Journal
BRITISH JOURNAL OF CANCER
Volume 100, Issue 8, Pages 1213-1218Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/sj.bjc.6605000
Keywords
chemical synthetic lethality; chemical genetic interactions; genetic synthetic lethality; oncogenes; tumour suppressor genes; RNAi
Categories
Funding
- Public Health Service National Cancer Institute
- German Israeli Foundation (GIF)
Ask authors/readers for more resources
A promising direction in the development of selective less toxic cancer drugs is the usage of synthetic lethality concept. The availability of large-scale synthetic low-molecular-weight chemical libraries has allowed HTS for compounds synergistic lethal with defined human cancer aberrations in activated oncogenes or tumour suppressor genes. The search for synthetic lethal chemicals in human/mouse tumour cells is greatly aided by a prior knowledge of relevant signalling and DNA repair pathways, allowing for educated guesses on the preferred potential therapeutic targets. The recent generation of human/rodents genome-wide siRNAs, and shRNA-expressing libraries, should further advance this more focused approach to cancer drug discovery. British Journal of Cancer (2009) 100, 1213-1218. doi: 10.1038/sj.bjc.6605000 www.bjcancer.com Published online 24 March 2009 (C) 2009 Cancer Research UK
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available